Tuesday 21 March 2023

12:30

Sir Jon Symonds & Sir John Bell

The outlook for life sciences in the UK

Hear from the two Vice Co-Chair’s about the Life Sciences Scale-Up Taskforce Report and Recommendations to address the scale-up barriers for innovative Life Science Companies in the UK.

Sir Jon Symonds, Sir John Bell
Chair of the Board of GSK; Regius Professor of Medicine at Oxford University

Jon Symonds was appointed to the Board of GSK as Chair in Sept 2019. Jon served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG.

John Bell is Regius Professor of Medicine at Oxford University and Government Advisor on Life Sciences. He is Chairman of the Gates Foundation Global Health Advisory Board and sits on the board of Genomics England Limited. John led the UK Life Sciences Industrial Strategy between 2015-2019, was President of the Academy of Medical Sciences and has helped to create (either as Founder or Founding Director) 5 Biotech companies. He was a Board Member at Roche AG for 19 years.

Sir Jon Symonds, Sir John Bell

Chair of the Board of GSK; Regius Professor of Medicine at Oxford University

Jon Symonds was appointed to the Board of GSK as Chair in Sept 2019. Jon served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG.

John Bell is Regius Professor of Medicine at Oxford University and Government Advisor on Life Sciences. He is Chairman of the Gates Foundation Global Health Advisory Board and sits on the board of Genomics England Limited. John led the UK Life Sciences Industrial Strategy between 2015-2019, was President of the Academy of Medical Sciences and has helped to create (either as Founder or Founding Director) 5 Biotech companies. He was a Board Member at Roche AG for 19 years.

You can add Pi Capital to your homescreen. Tap and then Add to homescreen